Bioprocessing International (BPI) 2024
Undeniable CRISPR FTO: Combining Cas-CLOVER IP with Foundational CRISPR/Cas9 IP from the CVC
Speaker: Jack Crawford, CEO
Abstract
Based on client feedback, the most important challenge companies face when adopting CRISPR technology for commercial cell line engineering is the complex landscape of intellectual property (IP). Multiple ownership of CRISPR/Cas9 patents has created uncertainty regarding commercial freedom to operate (FTO). This presentation will showcase how Demeetra has combined its own Cas-CLOVER IP with the CVC, key holders of foundational CRISPR IP, clearing the path for our clients to obtain straightforward commercial licenses with undeniable FTO.